Yuxin Cui1, B O Wu1,2, Valentina Flamini1, Bronwen A J Evans1,3, Deshan Zhou2, Wen G Jiang4. 1. Cardiff China Medical Research Collaborative, Cardiff University School of Medicine, Cardiff, U.K. 2. Department of Histology and Embryolog, Cancer Institute, Key Laboratory of Cancer Metastasis (Beijing), Capital Medical University, Beijing, P.R. China. 3. Institute of Molecular and Experimental Medicine, School of Medicine, Cardiff University, Cardiff, U.K. 4. Cardiff China Medical Research Collaborative, Cardiff University School of Medicine, Cardiff, U.K. jiangw@cf.ac.uk.
Abstract
BACKGROUND/AIM: Overexpression of erythropoietin-producing hepatocellular A1 (EPHA1), a member of the EPH super family, is frequently observed in various cancer types. The dysregulated interaction of EPHA1 with its ligand Ephrin A1 has been linked to the progression of ovarian cancer (OC). However, the contribution of EPHA1 in the regulation of the aggressive properties of OC cells remains unknown. MATERIALS AND METHODS: In this study we investigated the differential expression of EPHA1 in human OC cells. The EPHA1 gene was knocked-down using the CRISPR/Cas9 technique to evaluate its effect on the progressive properties of OC cells. RESULTS: After EPHA1 was knocked-down using a CRISPR/CAS9 genomic editing system in OC cells (SKOV3 and COV504), we observed cell-cycle arrest at the G0/G1 phases in both OC cell lines. Knockdown of EPHA1 in the two OC cells inhibited their aggressive traits, including proliferation, invasion and migration, as well as improving their attachment to extracellular matrix. EPHA1 may play a role in OC through its regulation of multiple signaling pathways, such as matrix metalloproteinase-2 (MMP2), extracellular signal-regulated kinase 2 (ERK2) and proto-oncogene c-MYC. CONCLUSION: EPHA1 may promote the aggression of some OC cells and, thus, be considered a potential therapeutic target for the treatment of malignant OC. Copyright
BACKGROUND/AIM: Overexpression of erythropoietin-producing hepatocellular A1 (EPHA1), a member of the EPH super family, is frequently observed in various cancer types. The dysregulated interaction of EPHA1 with its ligand Ephrin A1 has been linked to the progression of ovarian cancer (OC). However, the contribution of EPHA1 in the regulation of the aggressive properties of OC cells remains unknown. MATERIALS AND METHODS: In this study we investigated the differential expression of EPHA1 in human OC cells. The EPHA1 gene was knocked-down using the CRISPR/Cas9 technique to evaluate its effect on the progressive properties of OC cells. RESULTS: After EPHA1 was knocked-down using a CRISPR/CAS9 genomic editing system in OC cells (SKOV3 and COV504), we observed cell-cycle arrest at the G0/G1 phases in both OC cell lines. Knockdown of EPHA1 in the two OC cells inhibited their aggressive traits, including proliferation, invasion and migration, as well as improving their attachment to extracellular matrix. EPHA1 may play a role in OC through its regulation of multiple signaling pathways, such as matrix metalloproteinase-2 (MMP2), extracellular signal-regulated kinase 2 (ERK2) and proto-oncogene c-MYC. CONCLUSION:EPHA1 may promote the aggression of some OC cells and, thus, be considered a potential therapeutic target for the treatment of malignant OC. Copyright
Authors: Lidia Moyano-Galceran; Katrin Höpfner; Joonas Jukonen; Elina A Pietilä; Laura Lehtinen; Kaisa Huhtinen; Erika Gucciardo; Johanna Hynninen; Sakari Hietanen; Seija Grénman; Päivi M Ojala; Olli Carpén; Kaisa Lehti Journal: Sci Rep Date: 2021-04-23 Impact factor: 4.379
Authors: Karina D Rysenkova; Ekaterina V Semina; Maxim N Karagyaur; Anna A Shmakova; Daniyar T Dyikanov; Petr A Vasiluev; Yury P Rubtsov; Kseniya A Rubina; Vsevolod A Tkachuk Journal: Oncotarget Date: 2018-06-29